Drug and Therapeutics Bulletin 2005;43:25-28; doi:10.1136/dtb.2005.43425
Copyright © 2005 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Simvastatin over the counter

Relevant BNF section: 2.12

In July 2004, simvastatin 10mg was reclassified in the UK from a Prescription-only medicine (PoM) to a Pharmacy (P) medicine and launched as Zocor Heart-Pro (Johnson & Johnson.MSD Consumer Pharmaceuticals). It is the first statin in the world to be sold without prescription. Zocor Heart-Pro is licensed to reduce the risk of a first major coronary heart disease (CHD) event in people likely to be at "moderate risk" of such problems. Here we review the rationale and process for reclassifying simvastatin 10mg as an over-the-counter product.




This article has been cited by other articles:


Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
T. M. Reynolds, A. Mardani, P. J. Twomey, and A. S. Wierzbicki
Targeted versus global approaches to the management of hypercholesterolaemia
The Journal of the Royal Society for the Promotion of Health, September 1, 2008; 128(5): 248 - 254.
[Abstract] [PDF]

Home page
 CirculationHome page
A. M. Gotto Jr
Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease
Circulation, September 19, 2006; 114(12): 1310 - 1314.
[Full Text] [PDF]

Home page
 HeartHome page
P Mcelduff, M Jaefarnezhad, and P N Durrington
American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively
Heart, September 1, 2006; 92(9): 1213 - 1218.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Sleight, H. Pouleur, and F. Zannad
Benefits, challenges, and registerability of the polypill
Eur. Heart J., July 2, 2006; 27(14): 1651 - 1656.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2005 BMJ Publishing Group Ltd.